Ovid Therapeutics Inc.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | $33.8M | $50.0M | $9.6M | $6.6M |
| SG&A Expense | $19.1M | $15.0M | $12.9M | $6.6M |
| Operating Income | $-52.9M | $-65.0M | $-22.5M | $-13.2M |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | — | — | — | — |
| Income Tax Expense | $0 | $0 | — | — |
| Net Income | $-52.0M | $-64.8M | $-22.4M | $-13.2M |
| Net Margin | — | — | — | — |
| EPS (Basic) | $-2.11 | $-3.35 | $-2.28 | $-1.36 |
| EPS (Diluted) | $-2.11 | $-3.35 | $-2.28 | $-1.36 |
| Shares Outstanding (Basic) | 24.7M | 24.6M | 9.8M | — |
| Shares Outstanding (Diluted) | 24.7M | 24.6M | 9.8M | — |
| Dividends Per Share | — | — | — | — |